The Landscape of Prostate Tumor Methylation.

A compendium of 3,001 multi-ancestry prostate methylomes identifies four epigenomic subtypes that risk-stratify patients from normal tissue through poly-metastatic disease.

• Why it matters: Prostate cancer shows major clinical and molecular heterogeneity, but its epigenomic heterogeneity is less mapped than its genomic counterpart.
• What they did: The study built a methylation compendium across disease stages and used a subset of 884 samples with multi-omic DNA and/or RNA data to link methylation with DNA copy number and gene regulation.
• The result: It defines epigenetic dysregulation signatures for 15 clinico-molecular features, including predictive models for patient outcome that are synergistic with clinical prognostic features.

AI summary of the abstract · may contain errors · not medical advice · read the paper.